KOSDAQBiotech & Pharma217730

Kangstem Biotech

₩1,679▼ 1.93%2026-11-18 close
Market Cap
₩157.9B
Turnover
₩200M
Volume
140K
Shares out.
94.1M
PER
—
PBR
3.2×
EPS
-₩131
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Kangstem: Partnering Is the Test After OSCA Phase 2a

Kangstem presented OSCA's Phase 2a data at an international meeting, but revenue has fallen and quarterly losses continue, so follow-on trials and partnering results are the next checkpoints.

  1. 1

    Revenue has declined for three straight years from 2023 through 2025, reaching KRW 3.57 billion in 2025.

  2. 2

    The company has posted operating losses for four consecutive years through 2025, with a 2025 operating loss of KRW 17.7 billion and an operating margin of -494.6%.

  3. 3

    Losses have continued for three straight quarters from the first quarter of 2026 through the third, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 12.3 billion.

  4. 4

    OSCA's Phase 2a results were presented orally at ACR Convergence 2026 in the United States on November 11, 2026 (local time).

  5. 5

    The debt-to-equity ratio fell from 70.5% in 2022 to 18.0% in 2025, and total equity at the end of 2025 stood at KRW 69.1 billion.

02

Business structure

Kangstem Biotech develops and manufactures cell therapies based on umbilical cord blood-derived stem cells, and its lead pipeline is the knee osteoarthritis candidate OSCA.

OSCA is a single intra-articular injection that combines umbilical cord blood-derived mesenchymal stem cells with an acellular cartilage matrix, aiming to relieve pain and restore joint tissue.

According to Jobkorea company data as of March 2026, revenue mix is 55% CDMO, 30% GD11, 12% stem cell culture media and 3% other. CDMO, the largest segment, depends on contract development and manufacturing demand, so client development schedules can flow directly into results.

The stem cell segment weakened after the distribution agreement for Furestem-AD was terminated. Cosmetics sales also declined, which a company commentary on WiseReport cited as a factor behind the weaker results. A subsidiary runs an exosome-based drug discovery business.

The company says its skin and hair follicle organoid platform is a tool global pharma firms are evaluating to make preclinical and nonclinical work more efficient, and its in-house skin organoid platform SKINOID has been presented as usable for drug and device evaluation and high-throughput screening.

In July 2026, a patent on skin organoids was selected for the 2026 Top 30 Health R&D Achievements announced by the Ministry of Health and Welfare and partner agencies. Within the Korean standard industry classification for biological preparation manufacturing, its revenue ranks 34th.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩500M-₩4.2B−864.6%
2025Q4———
2026Q1₩800M-₩4.6B−567.6%
2026Q2₩600M-₩6.1B−944.3%
2026Q3₩600M-₩5.3B−869.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16.3B-₩20.6B-₩20.2B−126.1%−41.0%70.5%
2023₩12.7B-₩22.8B-₩21.9B−179.3%−45.7%82.5%
2024₩7.7B-₩14.8B-₩8B−191.6%−18.5%29.7%
2025₩3.6B-₩17.7B-₩10.5B−494.6%−15.3%18.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue went from KRW 16.3 billion in 2022 to KRW 12.7 billion in 2023 (down 22.1% year on year), KRW 7.75 billion in 2024 (down 39.0%) and KRW 3.57 billion in 2025 (down 53.9%), declining for three consecutive years from 2023 through 2025. 2022 was the largest year and 2025 the smallest within 2022 to 2025.

Operating losses were KRW 20.6 billion in 2022, KRW 22.8 billion in 2023, KRW 14.8 billion in 2024 and KRW 17.7 billion in 2025, making four consecutive years of losses from 2022 through 2025.

The loss narrowed in 2024 and widened again in 2025, when revenue fell by more than half and the operating margin dropped to -494.6%. The operating margin was -126.1% in 2022, -179.3% in 2023 and -191.6% in 2024, so the loss rate widened steadily before 2025.

Net loss attributable to controlling shareholders was KRW 20.2 billion in 2022, KRW 21.9 billion in 2023, KRW 7.99 billion in 2024 and KRW 10.5 billion in 2025. The consolidated net loss including non-controlling interests was KRW 23.2 billion in 2023, larger than the controlling-shareholder figure that year.

The debt-to-equity ratio fell from 70.5% in 2022 and 82.5% in 2023 to 29.7% in 2024 and 18.0% in 2025. At the end of 2025, total equity was KRW 69.1 billion, of which KRW 68.6 billion belonged to controlling shareholders, and total liabilities were KRW 12.4 billion.

Operating cash flow was negative in all four years: KRW -18.9 billion in 2022, KRW -16.5 billion in 2023, KRW -19 billion in 2024 and KRW -11.7 billion in 2025, the smallest outflow of the period.

Quarterly revenue rose from KRW 485 million in the third quarter of 2025 to KRW 805 million in the first quarter of 2026, then fell to KRW 642 million in the second quarter (down 20.2% quarter on quarter) and KRW 613 million in the third quarter (down 4.5% quarter on quarter, up 26.3% year on year), so it has declined for two straight quarters since the first quarter of 2026.

Operating losses were KRW 4.19 billion in the third quarter of 2025, KRW 4.57 billion in the first quarter of 2026, KRW 6.06 billion in the second quarter and KRW 5.33 billion in the third quarter.

The third-quarter 2026 loss narrowed from the prior quarter but widened from a year earlier, so the quarterly direction is mixed.

The net loss attributable to controlling shareholders was KRW 4.56 billion in the first quarter of 2026, KRW 6.25 billion in the second and KRW 5.18 billion in the third, three straight quarters of losses, and the total over the last four quarters (fourth quarter of 2025 through third quarter of 2026) was KRW 12.3 billion.

05

Industry analysis

In knee osteoarthritis treatment, Kangstem's stated point of difference is joint structure modification. At a Korean bio forum in November 2026, the company's research head said no therapy has yet been shown to structurally improve osteoarthritis.

That is the company's own claim and has not been compared directly with other treatments. OSCA targets patients with moderate knee osteoarthritis (Kellgren-Lawrence grade 2 to 3), a different indication from products aimed at severe patients.

In Korean knee degenerative arthritis cell therapy, a Korean cell-therapy group's affiliate announced Phase 3 topline success for an autologous fat-derived stem cell product in May 2021. Commentary at the time urged caution about calling a Phase 3 result a success before regulatory approval.

Kangstem's main revenue source, CDMO, competes in a market where large contract manufacturers such as Samsung Biologics lead, and the scale and client base differ widely. Cell therapy developers often have thin revenue bases, so their ability to raise funds during clinical development is a key variable.

Kangstem also carried out a shareholder-allotment rights offering worth KRW 39 billion in 2021, so capital raising has been part of its funding history.

06

Outlook

The nearest checkpoint the company has highlighted is the scientific presentation of OSCA's Phase 2a data. An oral presentation was given at ACR Convergence 2026 in Orlando on November 11, 2026 (local time).

In a placebo-controlled Phase 2a trial of 113 patients with moderate knee osteoarthritis, the company said pain and knee function measures at 24 weeks improved statistically significantly versus placebo. It also described positive changes in some detailed MRI-based joint structure measures.

The company said it plans to link Phase 2b and Phase 3 efficiently to shorten development time. It was invited to the J.P.

Morgan Healthcare Conference in January 2026, and in the first half of 2026 said it would hold partnering talks with more than 20 global companies at BIO USA 2026 covering OSCA and its organoid platform. The discussed models include co-development, licensing and commercialization.

According to the company, the organoid platform fits pharma demand for more efficient preclinical and nonclinical work. The talks, however, remain at the proposal and discussion stage, and the company releases do not specify contract terms or timing.

The next checkpoints are the timing of entry into Phase 2b, whether any partnering agreement is disclosed, and the revenue mix shown in the 2026 annual report. For the stem cell segment, how revenue recovers after the distribution agreement termination remains an open question.

07

Valuation

PER
—
PBR
3.2×
ROE
-21.1%
EPS
-₩131
BPS
₩552
Dividend per share
₩0

Earnings-based multiples cannot be calculated because the company has posted net losses over the last four quarters. Measured against the KRW 68.6 billion of equity attributable to controlling shareholders, the price-to-book ratio shows that market value carries a large premium over book net assets.

That structure can be read as pricing in pipeline and partnering expectations to a considerable degree rather than current earnings. The dividend yield is effectively nil, so shareholder return offers little support to the valuation.

On a multi-year view, the financial burden is easing: the debt-to-equity ratio fell from 70.5% in 2022 to 18.0% in 2025, and the operating cash outflow in 2025 of KRW 11.7 billion was the smallest of the four years.

Operating losses, however, widened to KRW 17.7 billion in 2025 from KRW 14.8 billion in 2024, and the third-quarter 2026 loss narrowed from the prior quarter but widened from a year earlier, so the direction of earnings recovery varies by quarter.

Under the same multiple, market interpretation could shift considerably depending on the OSCA trial and partnering outcomes.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Structure-related signals in the OSCA Phase 2a

The company said both the middle and high dose groups in its Phase 2a showed statistically significant improvement in pain and joint function. In MRI-based assessment, cartilage repair tissue scores improved in both dose groups, and the middle dose group reached statistical significance.

Because the data were presented orally at an international meeting, the company's structure-modification claim has entered academic review.

Global partnering talks and development plan

The company announced an invitation to the J.P. Morgan Healthcare Conference in January 2026, and said it planned talks with more than 20 global companies at BIO USA 2026. Which contract form the talks lead to, whether co-development, licensing or commercialization, is the next point to check. It also presented a plan to link Phase 2b and Phase 3 efficiently to shorten the development timeline.

Organoid platform and external recognition

The company describes its skin and hair follicle organoid platform as an area global pharma firms are considering for more efficient nonclinical work. Its in-house skin organoid platform SKINOID has been presented as usable for drug and device evaluation and high-throughput screening.

In July 2026, a skin organoid patent was selected for the 2026 Top 30 Health R&D Achievements, adding external recognition to the platform technology.

09

Bear factors

Three years of falling revenue and a terminated distribution deal

According to a company commentary on WiseReport, the termination of the Furestem-AD distribution agreement and lower cosmetics sales weighed on results. Revenue fell in both the second and third quarters of 2026, which raises questions about the pace of any recovery.

Continuing quarterly losses and cumulative net losses

The company has posted losses for three straight quarters from the first quarter through the third quarter of 2026, and the operating loss of KRW 6.06 billion in the second quarter was the largest in that span. The net loss attributable to controlling shareholders over the last four quarters totals KRW 12.3 billion.

Operating cash outflow in 2025 of KRW 11.7 billion was the smallest of the four years, but cash has flowed out in every year.

Clinical-stage uncertainty and a past re-run of a Phase 3

The OSCA Phase 2a enrolled 113 patients, and the structure-modification goal still needs confirmation in Phase 2b and Phase 3. The related product Furestem-AD ran a Phase 3 in 2018 and, after its 2019 results, changed its formulation and trial design and re-ran the Phase 3 under an IND approved in June 2021. It cannot be assumed that OSCA will follow the same path, but clinical-stage variables remain.

10

Risk factors

Clinical and regulatory

OSCA must advance through Phase 2b and Phase 3 after the 2a trial, and timing and value could shift with each stage's results and regulatory decisions. The 2a data currently public come from a conference presentation and company materials, not from an independent regulatory review. With 113 patients in the trial, whether the effect holds in larger populations is the central question.

Financing and cash burn

Operating losses have continued for four consecutive years from 2022, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 12.3 billion.

Of total equity of KRW 69.1 billion at the end of 2025, KRW 68.6 billion belongs to controlling shareholders, but with cash outflows continuing, expanding clinical work may require additional funding.

The company's 2021 shareholder-allotment rights offering of KRW 39 billion shows that capital raising has been part of its model.

Business mix and revenue base

CDMO, which accounts for 55% of revenue, can be affected by contract manufacturing demand and the circumstances of client companies. The termination of the Furestem-AD distribution agreement and lower cosmetics sales have weakened the stem cell business base.

Third-quarter 2026 revenue of KRW 613 million fell 4.5% from the prior quarter but rose 26.3% from a year earlier, so the quarterly trend is mixed.

11

What to watch next

  1. Not yet scheduled (ad hoc disclosure)

    Timing of OSCA's entry into Phase 2b and whether any co-development or licensing agreement with a global partner is disclosed. Whether contract terms and milestone payments are made public will be the basis for judging commercial value.

  2. Late March 2027

    Filing of the 2026 annual report, when full-year 2026 revenue, operating loss and operating cash flow, including fourth-quarter 2026 results, are confirmed in a periodic report. The operating margin in that report is the next checkpoint.

  3. May 15, 2027

    Statutory deadline for the first-quarter 2027 quarterly report. It is the point at which to check whether three straight quarters of losses and two straight quarters of declining revenue come to an end.

12

Overall view

Kangstem's disclosed results show revenue declining for three consecutive years from 2023 and operating losses for four consecutive years from 2022.

Losses have continued for three straight quarters from the first quarter through the third quarter of 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 12.3 billion.

On the financial side, the debt-to-equity ratio fell to 18.0% in 2025 and the operating cash outflow narrowed to KRW 11.7 billion. On the business side, OSCA's Phase 2a results were presented orally on November 11, 2026, introducing the structure-modification claim to an external audience.

However, the Phase 2a enrolled 113 patients, and Phase 2b, Phase 3, regulatory review and partnership agreements remain ahead. Because earnings-based multiples cannot be calculated and the price-to-book premium is large, the share price appears to reflect pipeline and partnering expectations to a considerable degree.

The next checkpoints are entry into Phase 2b and any disclosed agreements, the earnings and revenue mix in the 2026 annual report, and whether losses continue in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kangstem.com
  2. jobkorea.co.kr
  3. thebionews.net
  4. comp.wisereport.co.kr
  5. m.jobkorea.co.kr
  6. m.news.nate.com
  7. thebionews.net
  8. goinsider.kr
  9. kangstem.com
  10. thebionews.net
  11. ssl.pstatic.net
  12. file.alphasquare.co.kr
  13. mbiz.heraldcorp.com
  14. press9.kr
  15. yakup.com
  16. image-ppubs.uspto.gov
  17. biostar.co.kr
  18. ncbi.nlm.nih.gov

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis